PROKIDNEY CFO granted 600,000 stock options

Coulston James reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 03/03/2026 - 07:59 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Coulston James reported acquisition or exercise transactions in this Form 4 filing.

PROKIDNEY CORP. reported that its Chief Financial Officer, James Coulston, received a grant of employee stock options covering 600,000 shares of the company’s stock. The options were awarded at no cost on the grant date and are scheduled to vest in substantially equal monthly installments over a four-year period beginning March 1, 2026, tying the CFO’s potential upside closely to the company’s long-term performance.

Insider Trade Summary

Grant/Award: 600,000 shares

Grant/Award 1 txn

Insider Coulston James

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee stock option (right to buy)	600,000	$0.00	$0.00

Holdings After Transaction: Employee stock option (right to buy) — 600,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PROKIDNEY CORP. (PROK) report for its CFO?

PROKIDNEY CORP. reported that Chief Financial Officer James Coulston received an employee stock option grant for 600,000 shares. The award was made at no cost on the grant date and aligns his potential compensation with future company performance over several years.

How many shares are covered by James Coulston’s new stock options at PROKIDNEY CORP. (PROK)?

The new employee stock option grant to CFO James Coulston covers 600,000 shares of PROKIDNEY CORP. common stock. This entire amount is reflected as his derivative holdings after the transaction, subject to the award’s time-based vesting schedule over four years.

When do the PROKIDNEY CORP. (PROK) CFO’s stock options start vesting?

The employee stock options granted to PROKIDNEY CORP.’s CFO begin vesting on March 1, 2026. From that date, the options vest in substantially equal monthly installments, gradually increasing the portion he can exercise over the four-year vesting period.

Over what period do James Coulston’s PROKIDNEY CORP. (PROK) options vest?

The CFO’s 600,000-share option grant vests over a four-year period beginning March 1, 2026. Vesting occurs in substantially equal monthly installments, creating a long-term incentive structure that rewards continued service and alignment with shareholder interests.

Did the PROKIDNEY CORP. (PROK) CFO pay anything per share for the new stock options?

The Form 4 shows a per-share transaction price of 0.0000 for the CFO’s option grant. This indicates the options were awarded without a purchase price at the time of grant, consistent with typical equity-based compensation structures for senior executives.

How many derivative securities does the PROKIDNEY CORP. (PROK) CFO hold after this option grant?

Following the reported transaction, PROKIDNEY CORP.’s CFO holds 600,000 derivative securities related to this employee stock option award. This total reflects the full grant amount, which will become exercisable over time as the monthly vesting schedule progresses.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coulston James

(Last) (First) (Middle)

C/O PROKIDNEY CORP

2000 FRONTIS PLAZA BLVD, SUITE 250

(Street)

WINSTON-SALEM NC 27103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROKIDNEY CORP. [ PROK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$2.24	03/01/2026		A		600,000		(1)	03/01/2036	Class A Common Stock	600,000	$0	600,000	D

Explanation of Responses:

1. The option vests in substantially equal monthly installments over the four year period beginning on March 1, 2026.

	/s/ James Coulston	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.